5-Hydroxytryptamine (Serotonin): Definition and Clinical Significance
5-hydroxytryptamine (5-HT), commonly known as serotonin, is a monoamine neurotransmitter and hormone that regulates temperature, attention, behavior, gastrointestinal motility, secretion, immune function, and hemostasis 1.
Physiological Functions
Central Nervous System
In the CNS, serotonin functions as a neurotransmitter controlling:
- Autonomic neural activity and stress response
- Body temperature regulation
- Sleep-wake cycles
- Mood and emotional processing
- Appetite control 2
Peripheral Functions
Approximately 95% of body serotonin is synthesized by enterochromaffin (EC) cells in the gastrointestinal tract 3. Peripheral 5-HT regulates:
- Gastrointestinal system: Motor function, secretion, and intestinal motility 4, 3
- Cardiovascular system: Vascular tone, heart rate, and hemostasis through platelet activation 2
- Immune system: Modulates immune cell function, acting as both pro-inflammatory and anti-inflammatory depending on receptor binding 5
- Metabolic regulation: Energy metabolism through both central and peripheral signaling 2
- Respiratory drive and cell growth 2
Clinical Relevance
Pharmacological Targeting
SSRIs (Selective Serotonin Reuptake Inhibitors) selectively inhibit 5-HT reuptake at presynaptic nerve endings, increasing synaptic 5-HT concentration 4, 6. However, the AGA suggests against using SSRIs for IBS treatment due to lack of significant improvement in global symptoms or abdominal pain 4, 6.
Tricyclic antidepressants (TCAs) inhibit both serotonin and noradrenergic reuptake, providing beneficial effects on diarrhea and abdominal pain in IBS through peripheral and central actions 4, 6.
5-HT receptor-specific agents are emerging therapeutics:
- 5-HT₃ antagonists reduce diarrhea and are used as antiemetics 7, 8
- 5-HT₄ agonists improve constipation 7
- 5-HT₁B/1D agonists (triptans) treat acute migraine 9
- 5-HT₁F agonists (ditans like lasmiditan) represent newer migraine treatments 9
Critical Clinical Syndrome: Serotonin Syndrome
Serotonin syndrome is a potentially fatal condition caused by excessive serotonin levels, presenting with the clinical triad of mental status changes, autonomic hyperactivity, and neuromuscular abnormalities 1.
Key Diagnostic Features
- Onset: Minutes to hours (typically 6-24 hours) after adding/increasing serotonergic drugs 1
- Most diagnostic findings: Clonus and hyperreflexia in the setting of serotonergic drug use 1
- Common presentation: Myoclonus (57% of cases), tremor, hyperreflexia, agitated delirium 1
- Vital signs: Hyperthermia (≤41.1°C), tachycardia, tachypnea, hypertension 1
Hunter Criteria (Preferred Diagnostic Tool)
Diagnosis requires serotonergic drug use within 5 weeks PLUS any of:
- Spontaneous clonus
- Inducible clonus + (agitation OR diaphoresis)
- Ocular clonus + (agitation OR diaphoresis)
- Tremor + hyperreflexia
- Muscle rigidity + temperature >38°C + (ocular clonus OR inducible clonus) 1
Hunter criteria have higher sensitivity (84%) and specificity (97%) than older Sternbach criteria 1.
Management Algorithm
- Immediately discontinue all serotonergic agents 1
- Benzodiazepines for agitation (first-line) 1
- External cooling for hyperthermia (cooling blankets) 1
- IV fluids for autonomic instability 1
- For severe cases (temperature >41.1°C): Emergency sedation, neuromuscular paralysis, intubation 1
- Consider cyproheptadine (serotonin₂A antagonist) 1
Critical pitfall: Physical restraints worsen outcomes by exacerbating isometric contractions, increasing hyperthermia and lactic acidosis 1.
Mortality rate is approximately 11%, with severe cases progressing to rhabdomyolysis, metabolic acidosis, renal failure, seizures, and disseminated intravascular coagulopathy 1.
Drug Interaction Warnings
MAOIs are absolutely contraindicated with any serotonergic drug 10. When combining two non-MAOI serotonergic agents (SSRIs, SNRIs, TCAs, tramadol, dextromethorphan, amphetamines), start the second agent at low dose, increase slowly, and monitor intensively in the first 24-48 hours after dosage changes 10.
Emerging Therapeutic Applications
Recent evidence suggests targeting 5-HT pathways shows promise in:
- Tumor immunity modulation (macrophage polarization, T cell activity, PD-L1 expression)
- Combining SSRIs with immune checkpoint inhibitors
- Inhibiting metabolic enzymes (Tph1, MAO-A)
- Developing receptor subtype-specific agents (5-HT₇R antagonists) 11